Biotimize’s New Era

In early 2023, we partnered with Sthorm to build the first CDMO for biopharmaceuticals in Brazil!

Together we seek to develop new approaches to create a scenario where it is possible to democratize access to science and healing. That's how we're going to make a positive impact on people's lives.

With a new brand and a clear purpose, we are now focusing our personalized services on the biopharmaceutical sector, with the ability to develop projects from mammalian cells, bacteria, and yeast.

Since now, we are able to follow all the necessary steps to obtain biopharmaceuticals for pre-clinical studies. In doing so, we can speed up the arrival of new technologies (from both mammalian cells and microorganisms) to the market based on (under OECD GLP certification):

• Cell line development (vector design; transient transfection; streamlined CLD process; final clones with expected quality and expression levels; RCB generation)
• Process development and optimization (media and feed development; clone evaluation in shake flasks; PD in bioreactors 600 mL – 4L; harvest/clarification; chromatography – Protein A, AEX, CEX, IMAC, HIC, Mixed model; viral inactivation; formulation; sterile filtration; stability)
• Analytical and QC testing (Title – ELISA, Protein A, Bradford, A280; PQ – CEX, SES; Purity – SDS-Page; endotoxin; HCP; HCD; ELISA)
• Non-GMP production (production of up to 4L of transient expression or stable pools/clones for tox studies; low endotoxin purification)
• Bioprocess technical-economic analysis

See in the video our way to change the health market on the planet!